Sign inCreate account

Report workspace tools

NCT04729621COMPLETEDanonymous

A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis

Sponsor

Source record

Teva Pharmaceuticals USA

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

TVB-009, Prolia®

Indication / condition

AI-normalized

Osteoporosis, Postmenopausal

Intervention

Source record

TVB-009, Prolia®

Source & freshness

Source record

NCT ID

NCT04729621

Original source

ClinicalTrials.gov

Source last updated

Apr 18, 2024

Ingested at

Jun 04, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04729621

Title

A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis

Sponsor

Teva Pharmaceuticals USA

Status

COMPLETED

Phase

PHASE3

Condition raw

Osteoporosis, Postmenopausal

Condition normalized

Osteoporosis, Postmenopausal

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

TVB-009, Prolia®

Target normalized

TVB-009, Prolia®

Interventions

TVB-009, Prolia®

Public preview

Source record

Teva Pharmaceuticals USA conducted a Phase 3 clinical trial (NCT04729621) to evaluate the efficacy and safety of TVB-009P compared to Denosumab (Prolia®) in treating postmenopausal osteoporosis. The study involved 332 participants and was completed in June 2023.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04729621

Status

COMPLETED

Phase

PHASE3

Sponsor

Teva Pharmaceuticals USA

Executive brief

Investment-Ready Snapshot

Teva Pharmaceuticals USA conducted a Phase 3 clinical trial (NCT04729621) to evaluate the efficacy and safety of TVB-009P compared to Denosumab (Prolia®) in treating postmenopausal osteoporosis. The study involved 332 participants and was completed in June 2023.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 18, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04729621

Indication

Osteoporosis, Postmenopausal

Modality

monoclonal antibody

Target

TVB-009, Prolia®

Intervention

TVB-009, Prolia®

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.